Position in TRVI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$5,874,750
-$11,841,300 QoQ
Shares Held
315,000
-78.8% QoQ
Ownership
0.221%
of shares outstanding
% of Portfolio
0.54%
of 13F equity value
Holder Rank
#57
of 216 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TRVI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Octagon Capital Advisors LP holds $1,046,707,283 across 25 Biotechnology names. TRVI ranks #22 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
1,841,667 | $179,525,699 | |
| 2 | DFTX |
Definium Therapeutics, Inc.
|
2,950,000 | $138,768,000 | |
| 3 | ABVX |
Abivax S.A.
|
993,000 | $132,327,180 | |
| 4 | COGT |
Cogent Biosciences, Inc.
|
2,350,000 | $90,945,000 | |
| 5 | ALMS |
Alumis Inc.
|
2,830,700 | $79,655,898 | |
| 6 | AVBP |
ArriVent BioPharma, Inc.
|
1,971,054 | $68,474,415 | |
| 7 | TSHA |
Taysha Gene Therapies, Inc.
|
9,693,244 | $66,010,991 | |
| 8 | MIRM |
Mirum Pharmaceuticals, Inc.
|
338,900 | $39,675,023 |
All Filings in TRVI
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,874,750 | 315,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $17,716,050 | 1,485,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $35,243,800 | 2,815,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $25,757,250 | 2,815,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $20,085,840 | 3,672,000 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||